Table S1 Definition of adapted ACR JIA response. Table S2 Genes with âĽ3-fold differential expression between patients with SJIA and healthy controls, prior to canakinumab treatment. Table S3 List of independent ethics committees or institutional review boards (trial 1). Table S4 List of independent ethics committees or institutional review boards (trial 2). (DOCX 53 kb
Clinical features of studied groups of patients with RA and healthy controls. Table S2 The expressio...
Figure S1. Effect of osteogenic differentiation on both Ct-BdCs and AS-BdCs. Figure S2. Correlation ...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Table S1. List of genes included in transcriptional risk scores. Table S2. List of differentially ex...
Supplemental Data: Table S1. The clinical characteristics of samples in each JIA cohort. Table S2. G...
Figure S1. Effects of medication and sample time on gene expression. Figure S2. Correlation of betas...
Table S1. List of main diganoses in adult control group. Table S2. List of diseases in childrenâs ...
Table S1. List of regulated genes with fold change (FC) > 2 in patients with active disease (ad) ver...
Patients’ characteristics (immunohistochemistry studies on needle arthroscopic biopsies). Characteri...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Figure S1. Expression of ANXA3 using RT-PCR: delta Ct values (relative expression values related to ...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
The three treatment strategies in the BeSt for Kids study. Table representing the initial treatment ...
Table with total number of AEs by MedDRA SOC for retrospective and prospective visits in the Pharmac...
DAS28–4(CRP) of less than 2.6 and ACR/EULAR remission by study visit (ITT population). Abbreviations...
Clinical features of studied groups of patients with RA and healthy controls. Table S2 The expressio...
Figure S1. Effect of osteogenic differentiation on both Ct-BdCs and AS-BdCs. Figure S2. Correlation ...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Table S1. List of genes included in transcriptional risk scores. Table S2. List of differentially ex...
Supplemental Data: Table S1. The clinical characteristics of samples in each JIA cohort. Table S2. G...
Figure S1. Effects of medication and sample time on gene expression. Figure S2. Correlation of betas...
Table S1. List of main diganoses in adult control group. Table S2. List of diseases in childrenâs ...
Table S1. List of regulated genes with fold change (FC) > 2 in patients with active disease (ad) ver...
Patients’ characteristics (immunohistochemistry studies on needle arthroscopic biopsies). Characteri...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
Figure S1. Expression of ANXA3 using RT-PCR: delta Ct values (relative expression values related to ...
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...
The three treatment strategies in the BeSt for Kids study. Table representing the initial treatment ...
Table with total number of AEs by MedDRA SOC for retrospective and prospective visits in the Pharmac...
DAS28–4(CRP) of less than 2.6 and ACR/EULAR remission by study visit (ITT population). Abbreviations...
Clinical features of studied groups of patients with RA and healthy controls. Table S2 The expressio...
Figure S1. Effect of osteogenic differentiation on both Ct-BdCs and AS-BdCs. Figure S2. Correlation ...
BACKGROUND: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1...